2型糖尿病通路特异性多基因风险评分揭示18,217名中国2型糖尿病个体在临床表现、疾病进展和糖尿病并发症中的异质性
研究采用新开发的2型糖尿病硬聚类和软聚类通路特异性多基因风险评分(psPRS),在18,217名香港中国2型糖尿病患者中分析遗传易感性与临床特征、发病年龄、血糖恶化、肾脏和心血管结局的关联。结果显示,β细胞功能障碍和脂肪代谢障碍psPRS在正常体重者中较高;肥胖psPRS与更快的胰岛素治疗需求、终末期肾病和心血管疾病风险相关,而β细胞功能障碍psPRS与终末期肾病和心力衰竭风险降低相关。结论认为β细胞功能障碍和肥胖是疾病进展及并发症异质性的两大遗传驱动因素,psPRS有助于病因分层和精准糖尿病管理。
要点
- 正常体重2型糖尿病患者β细胞功能障碍和脂肪代谢障碍psPRS较高。
- 肥胖psPRS与临床需胰岛素治疗、终末期肾病和心血管疾病风险升高相关。
- β细胞功能障碍psPRS与终末期肾病和心力衰竭风险降低相关。
核心结论
- β细胞功能障碍和脂肪代谢障碍可能是正常体重个体2型糖尿病的驱动病理通路。
- β细胞功能障碍和肥胖的遗传风险是2型糖尿病疾病进展和并发症异质性的两大遗传驱动因素,且在不同祖先群体中共享。
- 2型糖尿病psPRS可能有助于根据病因进行患者分层并指导精准糖尿病管理。
研究设计与样本
- 研究纳入18,217名来自香港的中国2型糖尿病患者,采用新开发的硬聚类和软聚类通路特异性多基因风险评分(psPRS)评估个体对2型糖尿病相关病理生理通路的遗传易感性。
- 总2型糖尿病多基因风险评分(PRS)由全基因组显著2型糖尿病信号(n=1289)求和得出。
- 分析psPRS与心血管代谢特征、发病年龄、两个血糖恶化结局(临床需胰岛素治疗,定义为治疗期间间隔超过3个月连续两次HbA1c≥69 mmol/mol [8.5%]且使用两种或以上口服降糖药,以及启动胰岛素)、三个肾脏结局(白蛋白尿、终末期肾病和慢性肾脏病)和五个心血管结局的关联。
主要发现
- 大多数psPRS和总2型糖尿病PRS与更早及更年轻的2型糖尿病发病相关,但psPRS与临床结局呈现不同关联。
- 正常体重个体较超重个体具有更高的β细胞功能障碍和脂肪代谢障碍psPRS。
- 肥胖psPRS与更快的临床需胰岛素治疗进展相关(校正HR [95% CI] 1.09 [1.05, 1.13],p<0.0001)。
- 肥胖psPRS与终末期肾病(1.10 [1.04, 1.16],p=0.0007)和心血管疾病(1.10 [1.05, 1.16],p<0.0001)风险升高相关。
- β细胞功能障碍psPRS与终末期肾病风险降低(0.90 [0.85, 0.95],p=0.0001)和心力衰竭风险降低(0.83 [0.73, 0.93],p=0.0011)相关。
关键数值与推荐
- 临床需胰岛素治疗定义为治疗期间间隔超过3个月连续两次HbA1c≥69 mmol/mol [8.5%]且使用两种或以上口服降糖药。
- 总2型糖尿病PRS由1289个全基因组显著2型糖尿病信号求和得出。
- 肥胖psPRS与临床需胰岛素治疗进展的校正HR为1.09(95% CI 1.05, 1.13),p<0.0001。
- 肥胖psPRS与终末期肾病的校正HR为1.10(95% CI 1.04, 1.16),p=0.0007;与心血管疾病的校正HR为1.10(95% CI 1.05, 1.16),p<0.0001。
- β细胞功能障碍psPRS与终末期肾病的校正HR为0.90(95% CI 0.85, 0.95),p=0.0001;与心力衰竭的校正HR为0.83(95% CI 0.73, 0.93),p=0.0011。
临床怎么用
- 2型糖尿病psPRS可能有助于根据病因进行患者分层并指导精准糖尿病管理。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS/HYPOTHESIS: Type 2 diabetes is a complex and heterogeneous disease and the aetiological components underlying the heterogeneity remain unclear in the Chinese and East Asian population. Therefore, we aimed to investigate whether specific pathophysiological pathways drive the clinical heterogeneity in type 2 diabetes. METHODS: We employed newly developed type 2 diabetes hard-clustering and soft-clustering pathway-specific polygenic risk scores (psPRSs) to characterise individual genetic susceptibility to pathophysiological pathways implicated in type 2 diabetes in 18,217 Chinese patients from Hong Kong. The 'total' type 2 diabetes polygenic risk score (PRS) was summed by genome-wide significant type 2 diabetes signals (n=1289). We examined the associations between psPRSs and cardiometabolic profile, age of onset, two glycaemic deterioration outcomes (clinical requirement of insulin treatment, defined by two consecutive HbA1c values ≥69 mmol/mol [8.5%] more than 3 months apart during treatment with two or more oral glucose-lowering drugs, and insulin initiation), three renal (albuminuria, end-stage renal disease and chronic kidney disease) outcomes and five cardiovascular outcomes. RESULTS: Although most psPRSs and total type 2 diabetes PRS were associated with an earlier and younger onset of type 2 diabetes, the psPRSs showed distinct associations with clinical outcomes. In particular, individuals with normal weight showed higher psPRSs for beta cell dysfunction and lipodystrophy than those who were overweight. The psPRSs for obesity were associated with faster progression to clinical requirement of insulin treatment (adjusted HR [95% CI] 1.09 [1.05, 1.13], p<0.0001), end-stage renal disease (1.10 [1.04, 1.16], p=0.0007) and CVD (1.10 [1.05, 1.16], p<0.0001) while the psPRSs for beta cell dysfunction were associated with reduced incident end-stage renal disease (0.90 [0.85, 0.95], p=0.0001) and heart failure (0.83 [0.73, 0.93], p=0.0011). Major findings remained significant after adjusting for a set of clinical variables. CONCLUSIONS/INTERPRETATION: Beta cell dysfunction and lipodystrophy could be the driving pathological pathways in type 2 diabetes in individuals with normal weight. Genetic risks of beta cell dysfunction and obesity represent two major genetic drivers of type 2 diabetes heterogeneity in disease progression and diabetic complications, which are shared across ancestry groups. Type 2 diabetes psPRSs may help inform patient stratification according to aetiology and guide precision diabetes care.
引用
- Yu G, Tam CHT, Lim CKP, et al. Type 2 diabetes pathway-specific polygenic risk scores elucidate heterogeneity in clinical presentation, disease progression and diabetic complications in 18,217 Chinese individuals with type 2 diabetes. Diabetologia. 2024. PMID: 39531041. doi:10.1007/s00125-024-06309-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。